Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94


Project ECHO: A Telementoring Program for Cervical Cancer Prevention and Treatment in Low-Resource Settings.

Lopez MS, Baker ES, Milbourne AM, Gowen RM, Rodriguez AM, Lorenzoni C, Mwaba C, Msadabwe SC, Tavares JH, Fontes-Cintra G, Zucca-Matthes G, Callegaro-Filho D, Ramos-Martin D, Thiago de Carvalho I, Coelho R, Marques RM, Chulam T, Pontremoli-Salcedo M, Nozar F, Fiol V, Maza M, Arora S, Hawk ET, Schmeler KM.

J Glob Oncol. 2016 Oct 5;3(5):658-665. doi: 10.1200/JGO.2016.005504. eCollection 2017 Oct.


Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma.

Sivakumar S, Lucas FAS, McDowell TL, Lang W, Xu L, Fujimoto J, Zhang J, Futreal PA, Fukuoka J, Yatabe Y, Dubinett SM, Spira AE, Fowler J, Hawk ET, Wistuba II, Scheet P, Kadara H.

Cancer Res. 2017 Nov 15;77(22):6119-6130. doi: 10.1158/0008-5472.CAN-17-1605. Epub 2017 Sep 26.


Use of non-steroidal anti-inflammatory drugs in US adults: changes over time and by demographic.

Davis JS, Lee HY, Kim J, Advani SM, Peng HL, Banfield E, Hawk ET, Chang S, Frazier-Wood AC.

Open Heart. 2017 Apr 28;4(1):e000550. doi: 10.1136/openhrt-2016-000550. eCollection 2017.


Mutational Heterogeneity in APC and KRAS Arises at the Crypt Level and Leads to Polyclonality in Early Colorectal Tumorigenesis.

Gausachs M, Borras E, Chang K, Gonzalez S, Azuara D, Delgado Amador A, Lopez-Doriga A, San Lucas FA, Sanjuan X, Paules MJ, Taggart MW, Davies GE, Ehli EA, Fowler J, Moreno V, Pineda M, You YN, Lynch PM, Lazaro C, Navin NE, Scheet PA, Hawk ET, Capella G, Vilar E.

Clin Cancer Res. 2017 Oct 1;23(19):5936-5947. doi: 10.1158/1078-0432.CCR-17-0821. Epub 2017 Jun 23.


Building trust and diversity in patient-centered oncology clinical trials: An integrated model.

Hurd TC, Kaplan CD, Cook ED, Chilton JA, Lytton JS, Hawk ET, Jones LA.

Clin Trials. 2017 Apr;14(2):170-179. doi: 10.1177/1740774516688860. Epub 2017 Feb 7. Review.


Assessment of Compliance With Texas Legislation Banning Indoor UV Tanning by Minors.

Tripp MK, Gershenwald JE, Davies MA, Garcia J, Gritz ER, Hawk ET, Peterson SK.

JAMA Dermatol. 2016 Nov 9. doi: 10.1001/jamadermatol.2016.4068. [Epub ahead of print] No abstract available.


Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates.

Chitsazzadeh V, Coarfa C, Drummond JA, Nguyen T, Joseph A, Chilukuri S, Charpiot E, Adelmann CH, Ching G, Nguyen TN, Nicholas C, Thomas VD, Migden M, MacFarlane D, Thompson E, Shen J, Takata Y, McNiece K, Polansky MA, Abbas HA, Rajapakshe K, Gower A, Spira A, Covington KR, Xiao W, Gunaratne P, Pickering C, Frederick M, Myers JN, Shen L, Yao H, Su X, Rapini RP, Wheeler DA, Hawk ET, Flores ER, Tsai KY.

Nat Commun. 2016 Aug 30;7:12601. doi: 10.1038/ncomms12601.


Ernest Hawk Discusses the NCI-Designated Cancer Centers' Joint Statement on the HPV Vaccine.

Hawk ET.

Oncology (Williston Park). 2016 Jul;30(7):599-600. No abstract available.


Genomic Landscape of Colorectal Mucosa and Adenomas.

Borras E, San Lucas FA, Chang K, Zhou R, Masand G, Fowler J, Mork ME, You YN, Taggart MW, McAllister F, Jones DA, Davies GE, Edelmann W, Ehli EA, Lynch PM, Hawk ET, Capella G, Scheet P, Vilar E.

Cancer Prev Res (Phila). 2016 Jun;9(6):417-27. doi: 10.1158/1940-6207.CAPR-16-0081. Epub 2016 May 24.


Mechanisms of nonsteroidal anti-inflammatory drugs in cancer prevention.

Umar A, Steele VE, Menter DG, Hawk ET.

Semin Oncol. 2016 Feb;43(1):65-77. doi: 10.1053/j.seminoncol.2015.09.010. Epub 2015 Sep 10. Review.


Aspirin for Cancer Prevention: One Step Closer.

Vilar E, Maresso KC, Hawk ET.

JAMA Oncol. 2016 Jun 1;2(6):770-1. doi: 10.1001/jamaoncol.2015.6395. No abstract available.


Germline Genetic Variants in the Wnt/β-Catenin Pathway as Predictors of Colorectal Cancer Risk.

Hildebrandt MA, Reyes ME, Lin M, He Y, Nguyen SV, Hawk ET, Wu X.

Cancer Epidemiol Biomarkers Prev. 2016 Mar;25(3):540-6. doi: 10.1158/1055-9965.EPI-15-0834. Epub 2016 Jan 25.


When "Effective" Prevention Agents Fail to Elicit Anticipated Effects: Challenges in Trial Design.

Tsai KY, Hawk ET.

Cancer Prev Res (Phila). 2016 Feb;9(2):125-7. doi: 10.1158/1940-6207.CAPR-15-0432. Epub 2015 Dec 29. No abstract available.


Cohort Profile: The MD Anderson Cancer Patients and Survivors Cohort (MDA-CPSC).

Wu X, Hildebrandt MA, Ye Y, Chow WH, Gu J, Cunningham S, Zhao H, Hawk ET, Wagar E, Rodriguez A, Hamilton SR.

Int J Epidemiol. 2016 Jun;45(3):713-713f. doi: 10.1093/ije/dyv317. Epub 2015 Dec 20. No abstract available.


Molecular cancer prevention: Current status and future directions.

Maresso KC, Tsai KY, Brown PH, Szabo E, Lippman S, Hawk ET.

CA Cancer J Clin. 2015 Sep-Oct;65(5):345-83. doi: 10.3322/caac.21287. Epub 2015 Aug 18. Review.


Urinary PGE-M in colorectal cancer: predicting more than risk?

Colbert Maresso K, Vilar E, Hawk ET.

Cancer Prev Res (Phila). 2014 Oct;7(10):969-72. doi: 10.1158/1940-6207.CAPR-14-0215. Epub 2014 Jul 28.


Convergence of nanotechnology and cancer prevention: are we there yet?

Menter DG, Patterson SL, Logsdon CD, Kopetz S, Sood AK, Hawk ET.

Cancer Prev Res (Phila). 2014 Oct;7(10):973-92. doi: 10.1158/1940-6207.CAPR-14-0079. Epub 2014 Jul 24. Review.


Five National Cancer Institute-designated cancer centers' data collection on racial/ethnic minority participation in therapeutic trials: a current view and opportunities for improvement.

Hawk ET, Habermann EB, Ford JG, Wenzel JA, Brahmer JR, Chen MS Jr, Jones LA, Hurd TC, Rogers LM, Nguyen LH, Ahluwalia JS, Fouad M, Vickers SM.

Cancer. 2014 Apr 1;120 Suppl 7:1113-21. doi: 10.1002/cncr.28571.


Genome-wide methylation analysis shows similar patterns in Barrett's esophagus and esophageal adenocarcinoma.

Xu E, Gu J, Hawk ET, Wang KK, Lai M, Huang M, Ajani J, Wu X.

Carcinogenesis. 2013 Dec;34(12):2750-6. doi: 10.1093/carcin/bgt286. Epub 2013 Aug 29. Erratum in: Carcinogenesis. 2014 Mar;35(3):738.


Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced colorectal adenocarcinoma.

Lin M, Eng C, Hawk ET, Huang M, Lin J, Gu J, Ellis LM, Wu X.

Cancer. 2012 Dec 15;118(24):6188-98. doi: 10.1002/cncr.27653. Epub 2012 Jun 6.


Genetic polymorphisms in MicroRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients.

Lin M, Gu J, Eng C, Ellis LM, Hildebrandt MA, Lin J, Huang M, Calin GA, Wang D, Dubois RN, Hawk ET, Wu X.

Clin Cancer Res. 2012 Jul 15;18(14):3982-91. doi: 10.1158/1078-0432.CCR-11-2951. Epub 2012 Jun 1.


The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo.

Arber N, Lieberman D, Wang TC, Zhang R, Sands GH, Bertagnolli MM, Hawk ET, Eagle C, Coindreau J, Zauber A, Lanas A, Levin B.

Clin Ther. 2012 Mar;34(3):569-79. doi: 10.1016/j.clinthera.2012.02.001. Epub 2012 Mar 2.


Genetic variants within ultraconserved elements and susceptibility to right- and left-sided colorectal adenocarcinoma.

Lin M, Eng C, Hawk ET, Huang M, Greisinger AJ, Gu J, Ellis LM, Wu X, Lin J.

Carcinogenesis. 2012 Apr;33(4):841-7. doi: 10.1093/carcin/bgs096. Epub 2012 Feb 8.


Intake of red meat and heterocyclic amines, metabolic pathway genes and bladder cancer risk.

Lin J, Forman MR, Wang J, Grossman HB, Chen M, Dinney CP, Hawk ET, Wu X.

Int J Cancer. 2012 Oct 15;131(8):1892-903. doi: 10.1002/ijc.27437. Epub 2012 Mar 6.


The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenoma.

Chan AT, Hsu M, Zauber AG, Hawk ET, Bertagnolli MM.

Cancer Prev Res (Phila). 2012 Jan;5(1):61-72. doi: 10.1158/1940-6207.CAPR-11-0337. Epub 2011 Oct 26.


C-reactive protein and risk of colorectal adenoma according to celecoxib treatment.

Chan AT, Sima CS, Zauber AG, Ridker PM, Hawk ET, Bertagnolli MM.

Cancer Prev Res (Phila). 2011 Aug;4(8):1172-80. doi: 10.1158/1940-6207.CAPR-10-0403.


Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention.

Fischer SM, Hawk ET, Lubet RA.

Cancer Prev Res (Phila). 2011 Nov;4(11):1728-35. doi: 10.1158/1940-6207.CAPR-11-0166. Epub 2011 Jul 21. Review.


Conference Report: Eighth Annual AACR International Conference on Frontiers in Cancer Prevention Research.

Brewster AM, Patterson SL, Forman MR, Hughes-Halbert C, Limburg PJ, Ondrey FG, Paskett ED, Wetter DW, Hawk ET.

Cancer Prev Res (Phila). 2010 Aug;3(8):1044-8. doi: 10.1158/1940-6207.CAPR-10-0141. Epub 2010 Jul 27.


Genome-wide catalogue of chromosomal aberrations in barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis.

Gu J, Ajani JA, Hawk ET, Ye Y, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, Wang KK, Wu X.

Cancer Prev Res (Phila). 2010 Sep;3(9):1176-86. doi: 10.1158/1940-6207.CAPR-09-0265. Epub 2010 Jul 22.


Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial.

Bertagnolli MM, Hsu M, Hawk ET, Eagle CJ, Zauber AG; Adenoma Prevention with Celecoxib (APC) Study Investigators.

Cancer Prev Res (Phila). 2010 May;3(5):588-96. doi: 10.1158/1940-6207.CAPR-09-0271. Epub 2010 Apr 19.


Energy balance, the PI3K-AKT-mTOR pathway genes, and the risk of bladder cancer.

Lin J, Wang J, Greisinger AJ, Grossman HB, Forman MR, Dinney CP, Hawk ET, Wu X.

Cancer Prev Res (Phila). 2010 Apr;3(4):505-17. doi: 10.1158/1940-6207.CAPR-09-0263. Epub 2010 Mar 30.


Cancer prevention: from 1727 to milestones of the past 100 years.

Lippman SM, Hawk ET.

Cancer Res. 2009 Jul 1;69(13):5269-84. doi: 10.1158/0008-5472.CAN-09-1750. Epub 2009 Jun 2. Review.


Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial.

Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Breazna A, Kim K, Tang J, Rosenstein RB, Umar A, Bagheri D, Collins NT, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Hawk ET; Adenoma Prevention with Celecoxib Study Investigators.

Cancer Prev Res (Phila). 2009 Apr;2(4):310-21. doi: 10.1158/1940-6207.CAPR-08-0206. Epub 2009 Mar 31.


Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma.

Chan AT, Zauber AG, Hsu M, Breazna A, Hunter DJ, Rosenstein RB, Eagle CJ, Hawk ET, Bertagnolli MM.

Gastroenterology. 2009 Jun;136(7):2127-2136.e1. doi: 10.1053/j.gastro.2009.02.045. Epub 2009 Feb 21.


Cancer epidemiology, biomarkers & prevention and cancer prevention research: two journals, a common goal.

Rebbeck TR, Brown PH, Hawk ET, Lerman C, Paskett ED, Sellers TA, Lippman SM; CEBP Senior Editors and CaPR Deputy and Senior Editors.

Cancer Prev Res (Phila). 2008 Nov;1(6):393-5. doi: 10.1158/1940-6207.CAPR-08-0176. No abstract available.


Aberrant crypt foci in the adenoma prevention with celecoxib trial.

Cho NL, Redston M, Zauber AG, Carothers AM, Hornick J, Wilton A, Sontag S, Nishioka N, Giardiello FM, Saltzman JR, Gostout C, Eagle CJ, Hawk ET, Bertagnolli MM.

Cancer Prev Res (Phila). 2008 Jun;1(1):21-31. doi: 10.1158/1940-6207.CAPR-07-0011. Epub 2008 Apr 14.


Cancer epidemiology, biomarkers & prevention, and cancer prevention research: two journals, a common goal.

Rebbeck TR, Brown PH, Hawk ET, Lerman C, Paskett ED, Sellers TA, Lippman SM; CEBP Senior Editors and CaPR Deputy and Senior Editors.

Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):2903-5. doi: 10.1158/1055-9965.EPI-08-0888. No abstract available.


The Translational Research Working Group developmental pathway for lifestyle alterations.

Hawk ET, Greenwood A, Gritz ER, McTiernan A, Sellers T, Hursting SD, Leischow S, Grad O; Translational Research Working Group.

Clin Cancer Res. 2008 Sep 15;14(18):5707-13. doi: 10.1158/1078-0432.CCR-08-1262.


Translational Research Working Group developmental pathway for biospecimen-based assessment modalities.

Srivastava S, Gray JW, Reid BJ, Grad O, Greenwood A, Hawk ET; Translational Research Working Group.

Clin Cancer Res. 2008 Sep 15;14(18):5672-7. doi: 10.1158/1078-0432.CCR-08-1267.


The Translational Research Working Group developmental pathways: introduction and overview.

Hawk ET, Matrisian LM, Nelson WG, Dorfman GS, Stevens L, Kwok J, Viner J, Hautala J, Grad O; Translational Research Working Group.

Clin Cancer Res. 2008 Sep 15;14(18):5664-71. doi: 10.1158/1078-0432.CCR-08-1268. Epub 2008 Jul 8.


Statins in esophageal cancer cell lines: promising lead?

Hawk ET, Viner JL.

Am J Gastroenterol. 2008 Apr;103(4):838-41. doi: 10.1111/j.1572-0241.2007.01768.x. Epub 2008 Mar 24.


Workshop on imaging science development for cancer prevention and preemption.

Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Tatum JL, Dorfman GS, Jacobs P, Berg CD, Pomper MG, Birrer MJ, Tempero M, Higley HR, Petty BG, Sigman CC, Maley C, Sharma P, Wax A, Ginsberg GG, Dannenberg AJ, Hawk ET, Messing EM, Grossman HB, Harisinghani M, Bigio IJ, Griebel D, Henson DE, Fabian CJ, Ferrara K, Fantini S, Schnall MD, Zujewski JA, Hayes W, Klein EA, DeMarzo A, Ocak I, Ketterling JA, Tempany C, Shtern F, Parnes HL, Gomez J, Srivastava S, Szabo E, Lam S, Seibel EJ, Massion P, McLennan G, Cleary K, Suh R, Burt RW, Pfeiffer RM, Hoffman JM, Roy HK, Wang T, Limburg PJ, El-Deiry WS, Papadimitrakopoulou V, Hittelman WN, MacAulay C, Veltri RW, Solomon D, Jeronimo J, Richards-Kortum R, Johnson KA, Viner JL, Stratton SP, Rajadhyaksha M, Dhawan A; Workshop Program Committee.

Cancer Biomark. 2007;3(1):1-33.


Do statins prevent cancer?

Hawk ET, Viner JL.

Nat Clin Pract Oncol. 2006 Sep;3(9):478-9. No abstract available.


Celecoxib for the prevention of sporadic colorectal adenomas.

Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET; APC Study Investigators.

N Engl J Med. 2006 Aug 31;355(9):873-84.


Gene expression differences in normal esophageal mucosa associated with regression and progression of mild and moderate squamous dysplasia in a high-risk Chinese population.

Joshi N, Johnson LL, Wei WQ, Abnet CC, Dong ZW, Taylor PR, Limburg PJ, Dawsey SM, Hawk ET, Qiao YL, Kirsch IR.

Cancer Res. 2006 Jul 1;66(13):6851-60.


Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward.

Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin DM, Parnes HL, Siegfried JM, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee JJ, Dubinett SM, Engstrom PF, Meyskens FL Jr, O'Shaughnessy J, Hawk ET, Levin B, Nelson WG, Hong WK; AACR Task Force on Cancer Prevention.

Clin Cancer Res. 2006 Jun 15;12(12):3661-97. Review.


Selenomethionine treatment does not alter gene expression in normal squamous esophageal mucosa in a high-risk Chinese population.

Joshi N, Johnson LL, Wei WQ, Abnet CC, Dong ZW, Taylor PR, Limburg PJ, Dawsey SM, Hawk ET, Qiao YL, Kirsch IR.

Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):1046-7.


A methodologic analysis of chemoprevention and cancer prevention strategies for gastrointestinal cancer.

Jankowski JA, Hawk ET.

Nat Clin Pract Gastroenterol Hepatol. 2006 Feb;3(2):101-11. Review.


Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib.

Limburg PJ, Wei W, Ahnen DJ, Qiao Y, Hawk ET, Wang G, Giffen CA, Wang G, Roth MJ, Lu N, Korn EL, Ma Y, Caldwell KL, Dong Z, Taylor PR, Dawsey SM.

Gastroenterology. 2005 Sep;129(3):863-73.


Can animal models help us select specific compounds for cancer prevention trials?

Hawk ET, Umar A, Lubet RA, Kopelovich L, Viner JL.

Recent Results Cancer Res. 2005;166:71-87. Review.


Supplemental Content

Support Center